Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET

Company Participants

Christine Cassiano - Executive Vice President, Chief Corporate Officer and IR
David Chang - President, Chief Executive Officer and Co-Founder
Zachary Roberts - Executive Vice President of Research & Development and Chief Medical Officer
Geoffrey Parker - Executive Vice President and Chief Financial Officer

Conference Call Participants

Brian Chinn - JPMorgan
Jenna Li - Jefferies
Tyler Van Buren - TD Cowen
Jack Allen - Baird
Asthika Goonewardene - Truist
Brooke Schuster - William Blair
Matthew Biegler - Oppenheimer
John Newman - Canaccord
Benjamin Burnett - Stifel
Luca Issi - RBC Capital
Tashdid Hasan - Rodman & Renshaw
Reni Benjamin - Citizens JMP
Biren Amin - Piper Sandler
William Pickering - Bernstein

Operator

Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Second Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions].

I would now like to turn the call over to Christine Cassiano. You may begin.

Christine Cassiano

Thank you, operator, and welcome to all who have joined this call. After the market closed today, Allogene issued a press release that provides a business update and financial results for the second quarter of 2024. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session. We recognize that historically questions have been multifaceted, but note that we will endeavor to keep this call to under an hour.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, and 2024 financial guidance, among other things.

These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of the potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.